WebDec 20, 2024 · Direct chemotherapy-induced hepatotoxicity. Potentiation of preexisting liver disease, especially viral hepatitis. Altered hepatic drug metabolism due to underlying liver disease can result in higher or more persistent drug levels, thereby causing … WebJun 26, 2024 · Neurotoxicity from high-dose cytarabine, a pyrimidine metabolite used in treatment for acute myeloid leukemia, is a known but dose-limiting toxicity which has incidences in up to 14% in patients receiving high doses of the drug. Neurologic symptoms vary but range from somnolence and ataxia to more severe complications such as …
Full article: A review of treatment options employed in relapsed ...
WebIntermittent high-dose cytarabine (3 g/m2 in 8 to 12 doses) is extremely myelosuppressive. Similarly, the gastrointestinal toxicity is formidable and dose-limiting. Severe, and … WebLDAC: LDAC (Low dose cytarabine) has been evaluated in the setting of relapsed AML with results from a retrospective analysis of older patients with first relapse AML showing a CR rate of 17% and a median post-relapse survival of 5.6 months, which was not much better than for patients with best supportive care (3.2 months) [ 44 ]. hideaway thornaby
Protective effect of l-carnitine on oxidative stress in the liver of ...
WebDec 2, 2016 · Cytarabine (Ara C) is considered the most effective chemotherapeutic agent in acute myeloid leukemia (AML) treatment. Several studies suggest that single nucleotide polymorphisms (SNPs) within the genes involving metabolic pathway of Ara C could influence in treatment outcomes, although their clinical relevance remains undetermined. … WebDec 4, 2024 · First 2 cycles result in mild to moderate renal dysfunction, hepatotoxicity, cytopenias Reduce dose by 50% for severe liver impairment (Child-Pugh score for … WebKeywords---Hepatotoxicity, L-carnitine, Cytarabine, Liver enzyme, Antioxidants. Introduction The liver serves many metabolic functions. It has enormous regenerative capacity. howest ergotherapie